Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.38 |
| ▸ | IL2 | P60568 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | DHODH | Q02127 | 4/20 | 0.35 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15411982 | 0.82 | TRPA1 (0.37) | TLR7IL2CA1CA2DHODH | |
| SCHEMBL15411339 | 0.81 | MEN1 (0.50) | TLR7IL2TRPA1LMNAMEN1 | |
| SCHEMBL15410865 | 0.81 | CYP11B2 (0.49) | TLR8TMPRSS4LMNAMEN1KMT2A | |
| SCHEMBL15410871 | 0.79 | TLR8 (0.51) | TLR8TMPRSS4MEN1KMT2A | |
| SCHEMBL15410542 | 0.78 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL15409614 | 0.77 | RAB9A (0.52) | LMNAMEN1KMT2A | |
| SCHEMBL15411037 | 0.75 | ABCC9 (0.52) | LMNAMEN1KMT2A | |
| SCHEMBL15411345 | 0.74 | ITGB1 (0.44) | TLR7TRPA1MEN1KMT2A | |
| SCHEMBL15410528 | 0.72 | P2RX1 (0.45) | TLR8TMPRSS4MEN1KMT2A | |
| SCHEMBL15411502 | 0.72 | HTT (0.42) | TLR7IL2TRPA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018566-A1 | PALLADIUM(II)-CATALYZED SELECTIVE FLUORINATION OF BENZOIC ACIDS AND DERIVATIVES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018566-A1 | PALLADIUM(II)-CATALYZED SELECTIVE FLUORINATION OF BENZOIC ACIDS AND DERIVATIVES | AHR, DDT, AOC2 | TLR7 622/4885IL2 2951/4885CA1 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.